Related Experiment Video
Updated: May 2, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain
András Balogh1, Judit Bátor1, Lajos Markó2
1Department of Medical Biology, University of Pécs Medical School, Pécs, Hungary; Signal Transduction Research Group, János Szentágothai Research Centre, Pécs H-7624, Hungary.
Abstract:
Although the oncolytic potential of natural, non-engineered Newcastle disease virus (NDV) isolates are well-known, cellular mechanisms determining NDV sensitivity of tumor cells are poorly understood. The aim of the present study was to look for gene expression changes in PC12 pheochromocytoma cells infected with an attenuated NDV strain that may be related to NDV susceptibility. PC12 cells were infected with the NDV strain MTH-68/H for 12h at a titer corresponding to the IC₅₀ value. Total cytoplasmic RNA samples isolated from control and MTH-68/H-infected cells were analyzed using a rat specific Affymetrix exon chip. Genes with at least 2-fold increase or decrease in their expression were identified. MTH-68/H-induced gene expression changes of 9 genes were validated using quantitative reverse transcriptase PCR. A total of 729 genes were up- and 612 genes were down-regulated in PC12 cells infected with MTH-68/H. Using the DAVID functional annotation clustering tool, the up- and down-regulated genes can be categorized into 176 and 146 overlapping functional gene clusters, respectively. Gene expression changes affecting the most important signaling mechanisms (Toll-like receptor signaling, RIG-I-like receptor signaling, interferon signaling, interferon effector pathways, apoptosis pathways, endoplasmic reticulum stress pathways, cell cycle regulation) are analyzed and discussed in detail in this paper. NDV-induced gene expression changes described in this paper affect several regulatory mechanisms and dozens of putative key proteins that may determine the NDV susceptibility of various tumors. Further characterization of these proteins may identify susceptibility markers to predict the chances of virotherapeutic treatment of human tumors.
Insights
Newcastle disease virus (NDV) can infect tumor cells, but understanding why some are susceptible is key. This study identified gene expression changes in PC12 cells after NDV infection, revealing potential markers for predicting tumor treatment success.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Newcastle disease virus (NDV) exhibits oncolytic potential, yet the cellular mechanisms dictating tumor cell susceptibility remain largely unknown.
- Understanding these mechanisms is crucial for advancing NDV-based virotherapeutics.
Purpose of the Study:
- To investigate gene expression alterations in PC12 pheochromocytoma cells upon infection with an attenuated NDV strain (MTH-68/H).
- To identify genes and pathways associated with NDV susceptibility in tumor cells.
Main Methods:
- PC12 cells were infected with NDV strain MTH-68/H.
- Gene expression profiling was performed using Affymetrix exon arrays.
- Quantitative reverse transcriptase PCR (qRT-PCR) was used for validation.
- DAVID functional annotation clustering was employed for pathway analysis.
Main Results:
- A total of 729 genes were upregulated and 612 genes were downregulated in NDV-infected PC12 cells.
- Significant changes were observed in key signaling pathways including Toll-like receptor, RIG-I-like receptor, interferon signaling, apoptosis, endoplasmic reticulum stress, and cell cycle regulation.
- Expression changes in 9 specific genes were validated via qRT-PCR.
Conclusions:
- NDV infection induces significant gene expression changes in PC12 cells, impacting multiple regulatory pathways.
- These identified gene expression profiles and proteins may serve as susceptibility markers for predicting the efficacy of NDV-based virotherapy in human tumors.
- Further research into these proteins could refine patient selection for virotherapeutic treatments.

